| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Ratio | = | 1774.3 | M-1 s-1 |
| Ratio | = | 37.5 | M-1 s-1 |
| Ratio | = | 360.4 | M-1 s-1 |
| Ratio | = | 2900 | M-1 s-1 |
| Ratio | = | 10400 | M-1 s-1 |
| Ratio | = | 620.3 | M-1 s-1 |
| Ratio | = | 334.4 | M-1 s-1 |
| Standard Type | Activity Comment |
|---|---|
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Standard Type | Activity Comment |
|---|---|
| Activity | Substrate |
| Activity | Substrate |
| Activity | Substrate |
| Standard Type | Activity Comment |
|---|---|
| Activity | Substrate |
| Activity | Substrate |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 0.0075 | Rate | = | 7.5 | nM |
| 0.0024 | Rate | = | 2.4 | nM |
| 0.0105 | Rate | = | 10.5 | nM |
| 0.0152 | Rate | = | 15.2 | nM |
| Standard Type | Activity Comment |
|---|---|
| Activity | Substrate |
| Activity | Substrate |
| Activity | Substrate |
| Activity | Substrate |
| Activity | Substrate |
| Activity | Substrate |
| Activity | Substrate |
| Activity | Substrate |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Transacetylation rate | = | 13.29 | nM/mg*min |
| Transacetylation rate | = | 19.3 | nM/mg*min |
| Transacetylation rate | = | 9.73 | nM/mg*min |
| Transacetylation rate | = | 0.05 | nM/mg*min |
| Transacetylation rate | = | 0.03 | nM/mg*min |
| Transacetylation rate | = | 0.27 | nM/mg*min |
| Transacetylation rate | = | 0.11 | nM/mg*min |
| Transacetylation rate | = | 0.69 | nM/mg*min |
| Standard Type | Activity Comment |
|---|---|
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Standard Type | Activity Comment |
|---|---|
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Standard Type | Activity Comment |
|---|---|
| Activity | inducer [+] |
| Activity | inducer [+] |
| Activity | inducer [+] |
| Activity | inducer [+] |
| Activity | inducer [+] |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Adduct formation | = | 22.8 |
| Adduct formation | = | 2.2 |
| Standard Type | Activity Comment |
|---|---|
| Activity | carcinogenic activity |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Transacylation rate | = | 73.2 |
| Transacylation rate | = | 0.9 |
| CAS# | Chemical Code | TD50 | Species | Strain | Sex | Route | Tissue | Tumor | Opinion | Historic | Inadequate | Berkeley Mixes | Mandatory | Xpo Time | Xpr Time | Notes | Step | Lifetable | P-value | Lower Confidence | Upper Confidence | Plotted Symbol | Pound Sign | Ndoses | Curve | Ndsig | Control Total | Pool | Tumors Count | Data Number | ID | Paper Number | Source | PubMed ID | Citation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 78-79-5 | isr | 25800 | Mouse | B6C3F1 | Male | Inhalation | spleen | hemangiosarcoma | 0 | 0 | 80 | 96 | e | s | 0.566 | 3460 | 1.0E31 | $ | 1 | 0 | 1 | 49 | 0 | 1 | 8 | 43667 | 2258n | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 247 | Mouse | B6C3F1 | Female | Inhalation | pituitary gland | pars distalis adenoma | + | 0 | 80 | 105 | e | s | 0.022 | 97.1 | 1.0E31 | % | 2 | * | 2 | 49 | 0 | 1 | 8 | 43641 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 319 | Mouse | B6C3F1 | Female | Inhalation | Harderian gland | adenoma | + | 0 | 80 | 105 | e | s | 0.026 | 122 | 1.0E31 | $ | 2 | * | 2 | 49 | 0 | 2 | 8 | 43642 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 682 | Mouse | B6C3F1 | Female | Inhalation | spleen | hemangiosarcoma | + | h | 80 | 105 | e | s | 0.096 | 201 | 1.0E31 | $ | 2 | * | 2 | 50 | 0 | 1 | 8 | 43643 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 1.0E31 | Mouse | B6C3F1 | Female | Inhalation | liver | hepatocellular carcinoma | 0 | 0 | 80 | 105 | e | s | 1 | 322 | 1.0E31 | $ | 2 | 0 | 2 | 50 | 0 | 2 | 8 | 43644 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 1.0E31 | Mouse | B6C3F1 | Female | Inhalation | liver | hepatocellular adenoma | 0 | 0 | 80 | 105 | e | s | 1 | 310 | 1.0E31 | $ | 2 | 0 | 2 | 50 | 0 | 4 | 8 | 43645 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 1.0E31 | Mouse | B6C3F1 | Female | Inhalation | lung | alveolar/bronchiolar adenoma | 0 | 0 | 80 | 105 | e | s | 1 | 227 | 1.0E31 | $ | 2 | 0 | 2 | 50 | 0 | 5 | 8 | 43646 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 881 | Mouse | B6C3F1 | Male | Inhalation | Harderian gland | adenoma | + | 0 | 80 | 105 | e | s | 0 | 601 | 1430 | % | 5 | * | 5 | 47 | 0 | 4 | 8 | 43668 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 1570 | Mouse | B6C3F1 | Male | Inhalation | liver | hepatocellular adenoma | + | 0 | 80 | 105 | e | s | 0 | 891 | 4070 | $ | 5 | * | 5 | 50 | 0 | 11 | 8 | 43669 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 1660 | Mouse | B6C3F1 | Male | Inhalation | lung | alveolar/bronchiolar adenoma | + | 0 | 80 | 105 | e | s | 0 | 997 | 3620 | $ | 5 | * | 5 | 50 | 0 | 11 | 8 | 43670 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 6680 | Mouse | B6C3F1 | Male | Inhalation | lung | alveolar/bronchiolar carcinoma | + | 0 | 80 | 105 | e | s | 0 | 4020 | 28800 | $ | 5 | * | 5 | 50 | 0 | 0 | 8 | 43671 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 22200 | Mouse | B6C3F1 | Male | Inhalation | forestomach | squamous-cell carcinoma | + | 0 | 80 | 105 | e | s | 0.007 | 7680 | 740000 | $ | 5 | * | 5 | 50 | 0 | 0 | 8 | 43672 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 4850 | Mouse | B6C3F1 | Male | Inhalation | liver | hepatocellular carcinoma | + | 0 | 80 | 105 | e | s | 0.021 | 2000 | 1.0E31 | $ | 5 | * | 5 | 50 | 0 | 9 | 8 | 43673 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 15000 | Mouse | B6C3F1 | Male | Inhalation | Harderian gland | carcinoma | + | 0 | 80 | 105 | e | s | 0.016 | 6100 | 1.0E31 | $ | 5 | * | 5 | 47 | 0 | 0 | 8 | 43674 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 45000 | Mouse | B6C3F1 | Male | Inhalation | forestomach | squamous-cell papilloma | 0 | 0 | 80 | 105 | e | s | 0.068 | 11100 | 1.0E31 | $ | 5 | * | 5 | 50 | 0 | 0 | 8 | 43675 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 39000 | Mouse | B6C3F1 | Male | Inhalation | heart | hemangiosarcoma | + | h | 80 | 105 | e | s | 0.308 | 8070 | 1.0E31 | $ | 5 | * | 5 | 49 | 0 | 0 | 8 | 43676 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 150000 | Mouse | B6C3F1 | Male | Inhalation | lymphoreticular system | histiocytic sarcoma | 0 | 0 | 80 | 105 | e | s | 0.821 | 8450 | 1.0E31 | $ | 5 | * | 5 | 50 | 0 | 0 | 8 | 43677 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 78-79-5 | isr | 1.0E31 | Mouse | B6C3F1 | Male | Inhalation | spleen | hemangiosarcoma | 0 | 0 | 80 | 105 | e | s | 1 | 13500 | 1.0E31 | $ | 5 | 0 | 5 | 49 | 0 | 1 | 8 | 43678 | 2258o | Literature | 8901906 | M E :Placke;Toxicology,113,253-262;1996 | |||||
| 26675-46-7 | isu | 30000 | Mouse | Swiss Webster | Female | Inhalation | lung | alveolar-cell adenoma | - | 0 | 78 | 81 | 0 | s | 0.235 | 8670 | 1.0E31 | % | 2 | * | 2 | 92 | 0 | 15 | 5 | 40370 | 1879 | Literature | 3189921 | J M :Baden;Anesthesiology,69,750-753;1988 | |||||
| 26675-46-7 | isu | 1.0E31 | Mouse | Swiss Webster | Female | Inhalation | liver | basophil adenoma | - | 0 | 78 | 81 | 0 | s | 1 | 36000 | 1.0E31 | $ | 2 | 0 | 2 | 92 | 0 | 1 | 5 | 40371 | 1879 | Literature | 3189921 | J M :Baden;Anesthesiology,69,750-753;1988 |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Log rate | = | 0.09 |
| Log rate | = | 1.4 |
| Log rate | = | 0.87 |
| Log rate | = | 0.37 |
| Log rate | = | 1.79 |
| Log rate | = | 1.02 |
| Log rate | = | 1.18 |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 88.8 | Kd | = | 88800 | nM | |
| 0.4 | Kd | = | 400 | nM | |
| 5.9 | Kd | = | 5900 | nM | |
| 128.6 | Kd | = | 128600 | nM | Outside typical range |
| 48.8 | Kd | = | 48800 | nM | |
| 3.8 | Kd | = | 3800 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Protection | = | 47.6 | % |
| Protection | = | 35.9 | % |
| Protection | = | 39.1 | % |
| Protection | = | 32.4 | % |
| Protection | = | 31.1 | % |
| Protection | = | 54.5 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Protection | = | 46.1 | % |
| Protection | = | 30.5 | % |
| Protection | = | 15.7 | % |
| Protection | = | 26.3 | % |
| Protection | = | 34.7 | % |
| Protection | = | 55.2 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Protection | = | 28.3 | % |
| Protection | = | 8 | % |
| Protection | = | 23.1 | % |
| Protection | = | 0.3 | % |
| Protection | = | 6.6 | % |
| Protection | = | 38.2 | % |
| EXPID | PREFIX | CONCENTRATION_UNIT | CONCENTRATION | PANELNBR | CELLNBR | PANELNAME | CELLNAME | PANELCODE | M_GIPRCNT | N_GIPRCNT | STDDEV_GIPRCNT | EXP_COUNT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 88.231 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 87.1119 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 14.4371 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 89.7113 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 97.2463 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 90.0129 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 85.7031 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 30.8539 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 14.2896 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 85.8526 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 83.1036 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 84.2194 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 89.3237 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 85.6034 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 89.6643 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 91.2503 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 94.8714 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 93.7372 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 112.6132 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 73.375 | 1 | 0 | 1 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Protection | = | 32.2 | % |
| Protection | = | 2.9 | % |
| Protection | = | 1.9 | % |
| Protection | = | 8.3 | % |
| Protection | = | 0 | % |
| Protection | = | 17.6 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Protection | = | 54.9 | % |
| Protection | = | 5.9 | % |
| Protection | = | 34.9 | % |
| Protection | = | 1.4 | % |
| Protection | = | 26.9 | % |
| Protection | = | 58.4 | % |
| EXPID | PREFIX | CONCENTRATION_UNIT | CONCENTRATION | PANELNBR | CELLNBR | PANELNAME | CELLNAME | PANELCODE | M_GIPRCNT | N_GIPRCNT | STDDEV_GIPRCNT | EXP_COUNT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0809OS51 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 89.6274 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 94.0185 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 77.1805 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 76.1686 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 82.5618 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 88.7561 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 83.5845 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 92.7497 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 70.9555 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 58.7306 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 72.6041 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 90.3839 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 110.2345 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 97.6538 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 93.7697 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 56.4618 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 80.8893 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 79.078 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | -20.3008 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 72.0949 | 1 | 0 | 1 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Ki | = | 3.73 | min-1 |
| Ki | = | 0.09 | min-1 |
| Ki | = | 1.95 | min-1 |
| Ki | = | 0.07 | min-1 |
| Ki | = | 0.25 | min-1 |
| Ki | = | 0.22 | min-1 |
| Ki | = | 2.59 | min-1 |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 0.0209 | Rate | = | 20.9 | nM |
| 0.0053 | Rate | = | 5.3 | nM |
| 0.0205 | Rate | = | 20.5 | nM |
| 0.0268 | Rate | = | 26.8 | nM |
| 0.0201 | Rate | = | 20.1 | nM |
| 0.0096 | Rate | = | 9.6 | nM |
| Standard Type | Activity Comment |
|---|---|
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Standard Type | Activity Comment |
|---|---|
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |
| Activity | carcinogenic activity |